During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in ...
A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.
The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...
Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...
The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy for advanced or metastatic malignant pleural mesothelioma. The FDA approved frontline pembrolizumab (Keytruda) plus pemetrexed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback